EP3128008C0 - Double-stranded oligo rna and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases - Google Patents

Double-stranded oligo rna and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases

Info

Publication number
EP3128008C0
EP3128008C0 EP15772613.4A EP15772613A EP3128008C0 EP 3128008 C0 EP3128008 C0 EP 3128008C0 EP 15772613 A EP15772613 A EP 15772613A EP 3128008 C0 EP3128008 C0 EP 3128008C0
Authority
EP
European Patent Office
Prior art keywords
double
preventing
pharmaceutical composition
same
respiratory diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP15772613.4A
Other languages
German (de)
French (fr)
Other versions
EP3128008B1 (en
EP3128008A2 (en
EP3128008A4 (en
Inventor
Jeiwook Chae
Pyoung Oh Yoon
Boram Han
Mi Na Kim
Youngho Ko
Han Oh Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioneer Corp
Original Assignee
Bioneer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioneer Corp filed Critical Bioneer Corp
Publication of EP3128008A2 publication Critical patent/EP3128008A2/en
Publication of EP3128008A4 publication Critical patent/EP3128008A4/en
Application granted granted Critical
Publication of EP3128008B1 publication Critical patent/EP3128008B1/en
Publication of EP3128008C0 publication Critical patent/EP3128008C0/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP15772613.4A 2014-04-04 2015-04-06 Double-stranded oligo rna and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases Active EP3128008B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20140040699 2014-04-04
PCT/KR2015/003400 WO2015152693A2 (en) 2014-04-04 2015-04-06 Novel double-stranded oligo rna and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases

Publications (4)

Publication Number Publication Date
EP3128008A2 EP3128008A2 (en) 2017-02-08
EP3128008A4 EP3128008A4 (en) 2018-03-28
EP3128008B1 EP3128008B1 (en) 2024-05-29
EP3128008C0 true EP3128008C0 (en) 2024-05-29

Family

ID=54241409

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15772613.4A Active EP3128008B1 (en) 2014-04-04 2015-04-06 Double-stranded oligo rna and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases

Country Status (7)

Country Link
US (1) US10208309B2 (en)
EP (1) EP3128008B1 (en)
JP (1) JP6426268B2 (en)
KR (1) KR102208588B1 (en)
CN (2) CN112159807A (en)
BR (1) BR112016023004B1 (en)
WO (1) WO2015152693A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
CA2953216C (en) 2014-06-04 2020-12-22 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
AU2015349680A1 (en) 2014-11-21 2017-06-08 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
KR101861738B1 (en) 2016-08-24 2018-05-29 (주)바이오니아 Double Stranded Oligo RNA Structure Comprising miRNA
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US11613754B2 (en) 2017-02-20 2023-03-28 Northwestern University Toxic RNAi active seed sequences for killing cancer cells
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
WO2018213585A1 (en) * 2017-05-17 2018-11-22 Northwestern University Conjugation of peptides to spherical nucleic acids (snas) using tracelless linkers
CN112368382A (en) * 2018-05-25 2021-02-12 柏业公司 Dual-stranded oligonucleotides specific for amphiregulin gene and compositions comprising the same for preventing and treating fibrosis-related diseases and respiratory diseases
CN113454223B (en) * 2019-01-15 2024-09-13 柏业公司 DKK1 gene-targeted double-stranded oligonucleotide, construct comprising same, and hair loss prevention or hair growth composition comprising same
KR20210063137A (en) * 2019-11-22 2021-06-01 (주)바이오니아 A double-stranded oligonucleotide comprising CTGF specific sequence and a composition for treating and preventing fibrosis related diseases and respiratory related diseases
CA3178609A1 (en) * 2020-05-14 2021-11-18 Jun Hong Park Composition for preventing or treating obesity-related disease containing amphiregulin-specific double-stranded oligonucleotide structure
US11933781B2 (en) 2020-12-09 2024-03-19 The Regents Of The University Of Colorado Fibrosis model and methods of use thereof
CA3210813A1 (en) * 2021-03-08 2022-09-15 Han-Oh Park Composition for administration of double-stranded oligonucleotide structures using ultrasonic nebulizer for prevention or treatment of respiratory viral infection including covid-19, pulmonary fibrosis caused by viral infection, or respiratory disease

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034323A (en) 1989-03-30 1991-07-23 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
US5231020A (en) 1989-03-30 1993-07-27 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
US6005087A (en) 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
DE69429337T3 (en) 1993-04-02 2012-08-30 Anticancer Inc. METHOD FOR THE ADMINISTRATION OF SPATIAL COMPOSITIONS TO HAIR FOLLICLES
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6277967B1 (en) 1998-07-14 2001-08-21 Isis Pharmaceuticals, Inc. Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
US6175001B1 (en) 1998-10-16 2001-01-16 The Scripps Research Institute Functionalized pyrimidine nucleosides and nucleotides and DNA's incorporating same
EP1442143A4 (en) 2002-02-20 2005-02-16 Sirna Therapeutics Inc RNA INTERFERENCE MEDIATED INHIBITION OF BCL2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
EP1449538A1 (en) * 2003-02-21 2004-08-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation
US8168601B2 (en) 2004-08-16 2012-05-01 Immune Disease Institute, Inc. Method of delivering RNA interference and uses thereof
WO2006031901A2 (en) * 2004-09-10 2006-03-23 Somagenics, Inc. SMALL INTERFERING RNAs THAT EFFICIENTLY INHIBIT VIRAL GENE EXPRESSION AND METHODS OF USE THEREOF
WO2006039369A1 (en) 2004-09-29 2006-04-13 Alza Corporation Microparticles and nanoparticles containing a lipopolymer
TWI386225B (en) 2004-12-23 2013-02-21 Alcon Inc Rnai inhibition of ctgf for treatment of ocular disorders
AU2006280600B2 (en) 2005-08-17 2012-01-19 Bioneer Corporation Sirna-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
WO2007044468A2 (en) 2005-10-05 2007-04-19 The Cbr Institute For Biomedical Research, Inc. Method to treat flavivirus infection with sirna
EP2087113A2 (en) * 2006-10-11 2009-08-12 Fusion Antibodies Limited Combination therapy
JP2010507387A (en) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド Novel siRNA and method of using the same
EP2120940A2 (en) 2007-01-16 2009-11-25 Protelogiecs, Ltd. Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors
US8188060B2 (en) * 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
KR101087614B1 (en) 2008-12-31 2011-11-29 서울대학교산학협력단 Pharmaceuticla composition comprising siRNA specific for reduced expression-1 for treating the BCNU-resistance glioblastoma multiforme
AU2010226434A1 (en) 2009-03-20 2011-10-13 Egen, Inc. Polyamine derivatives
KR101224828B1 (en) * 2009-05-14 2013-01-22 (주)바이오니아 SiRNA conjugate and preparing method thereof
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US10202615B2 (en) * 2010-12-10 2019-02-12 Vanderbilt University Mammalian genes involved in toxicity and infection
CN103501821A (en) * 2011-03-08 2014-01-08 艾克塞斯制药公司 Targeted nanocarrier systems for delivery of actives across biological membranes
PL2736887T3 (en) 2011-07-29 2018-03-30 Karyopharm Therapeutics, Inc. Hydrazide containing nuclear transport modulators and uses thereof
PT3597644T (en) 2011-10-18 2021-11-03 Dicerna Pharmaceuticals Inc Amine cationic lipids and uses thereof
PL2796150T3 (en) 2011-12-15 2021-08-30 Bioneer Corporation Novel oligonucleotide conjugates and use thereof
CN107988227A (en) * 2012-01-05 2018-05-04 株式会社百奥尼 Efficient nanoparticle form double helix widow RNA structures and preparation method thereof
KR101241852B1 (en) 2012-06-28 2013-03-11 (주)바이오니아 siRNA conjugate and preparing method thereof
US20150259690A1 (en) * 2012-10-05 2015-09-17 Bioneer Corporation Amphiregulin-specific double-helical oligo-rna, double-helical oligo-rna structure comprising double-helical oligo-rna, and composition for preventing or treating respiratory diseases containing same

Also Published As

Publication number Publication date
BR112016023004A2 (en) 2018-07-03
BR112016023004B1 (en) 2023-12-05
EP3128008B1 (en) 2024-05-29
US10208309B2 (en) 2019-02-19
JP6426268B2 (en) 2018-11-21
JP2017512502A (en) 2017-05-25
KR102208588B1 (en) 2021-01-28
EP3128008A2 (en) 2017-02-08
WO2015152693A3 (en) 2015-11-26
CN106459974A (en) 2017-02-22
EP3128008A4 (en) 2018-03-28
US20170130231A1 (en) 2017-05-11
WO2015152693A2 (en) 2015-10-08
KR20150115687A (en) 2015-10-14
CN112159807A (en) 2021-01-01

Similar Documents

Publication Publication Date Title
EP3128008C0 (en) Double-stranded oligo rna and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases
IL256085B (en) A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment
HK1254074A1 (en) Methods and compositions for efficient delivery of nucleic acids and rna-based anti-microbials
HK1249103B (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
HK1251153A1 (en) Pharmaceutical composition and application thereof
IL265359B1 (en) Modified oligonucleotides and pharmaceutical compositions
HK1258393A1 (en) Compositions and methods of use of antibacterial drug combinations
HK1256674A1 (en) Deuterium-modified brigatinib derivatives, pharmaceutical compositions comprising same, and use thereof
HK1245113A1 (en) Pharmaceutical compositions and use thereof
GB201406172D0 (en) Therapy and pharmaceutical composition
ZA201607148B (en) Pharmaceutical composition including anti-fungal agent and steroid
IL280389A (en) A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment
EP3156054A4 (en) Medicine for preventing and/or treating stress-induced diseases
ZA201608558B (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
EP3377062C0 (en) Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases
PL3341481T3 (en) Microrna-328 anti-sense composition and therapeutic use
GB201519644D0 (en) Therapy and pharmaceutical composition
IL257689B (en) Pharmaceutical compositions and methods for the treatment of hypoxia-related diseases
EP3322817B8 (en) Oligonucleotides and use thereof
EP3116513A4 (en) Pharmaceutical compositions comprising rna and use for treating cancer
EP3348279A4 (en) Medicinal composition for preventing or treating inflammatory respiratory disease
EP3181144A4 (en) Medicinal composition for treating and/or preventing esophageal stenosis

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20161102

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 11/00 20060101ALI20171027BHEP

Ipc: A61K 48/00 20060101ALI20171027BHEP

Ipc: C12N 15/113 20100101AFI20171027BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20180227

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/113 20100101AFI20180221BHEP

Ipc: A61K 48/00 20060101ALI20180221BHEP

Ipc: A61P 11/00 20060101ALI20180221BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190128

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20231114

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015088841

Country of ref document: DE

U01 Request for unitary effect filed

Effective date: 20240529

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI

Effective date: 20240604

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240929

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240529

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240830